(Q34486480)

2 August 2017

1 reference

title

Antifungal susceptibility testing. New technology and clinical applications (English)

1 reference

2 August 2017

Pfaller MA

1

1 reference

PubMed ID

11780273

2 August 2017

Yu WL

series ordinal

2

1 reference

PubMed ID

11780273

2 August 2017

language of work or name

1 reference

1 December 2001

1 reference

Infectious Disease Clinics of North America

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

4

1 reference

2 August 2017

1227-1261

1 reference

The medical mycological iceberg

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Disseminated trichosporonosis: Meeting the challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of growth characteristics on blood agar and eosin methylene blue agar for the identification of Candida (Torulopsis) glabrata.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Quality control limits for broth microdilution susceptibility tests of ten antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Itraconazole resistance in Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Introduction to antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Clinical relevance of antifungal resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Susceptibility testing of fungi: current status of the standardization process

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Disseminated Infection with Fusarium in Recipients of Bone Marrow Transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses stu

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Mycoses caused by Candida lusitaniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of voriconazole pharmacodynamics using time-kill methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Amphotericin B resistance testing of Candida spp.: a comparison of methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Development of Fluconazole Resistance inCandida albicansCausing Disseminated Infection in a Patient Undergoing Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

The trailing end point phenotype in antifungal susceptibility testing is pH dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro evaluation of voriconazole against some clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

The spectrum of non-Candida fungal infections following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Standardized susceptibility testing of fluconazole: an international collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal susceptibility testing: technical advances and potential clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Collaborative investigation of variables in susceptibility testing of yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Detection of amphotericin B-resistant Candida isolates in a broth-based system

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal susceptibility testing of yeasts: a brief overview

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Use of a colorimetric system for yeast susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970192-6

7 January 2021

10.1016/S0891-5520(05)70192-6

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11780273